Implications for telehealth and pharma companies: While the proposal is still under review, it would reshape supply, access, and pricing if finalized

Key Comparative Insight Mounjaro generally delivers greater average weight loss (around ~23%) compared to Wegovys ~18% at current doses, but Wegovys upcoming 7.2 mg dose may match or even exceed that, with early trial data showing ~21% loss, and a third of patients losing more than 25% Pricing: UK Private Market Spotlight Mounjaro As of 1 September 2025 , UK private prices for the highest dose surged from ~122 to between 270330 per month , a dramatic increase of up to 170% Wegovy Remains considerably more affordable , with private monthly fees typically ranging between 85240 , depending on dose and provider Novo Nordisk has confirmed no planned price increases in the UK Switching: Tips for a Seamless Transition Dosage Alignment : Healthcare providers can match your current Mounjaro dose to an equivalent Wegovy dose (e.g., if you experienced side effects on Mounjaro, they may advise stepping down slightly on Wegovy initially) Avoiding Dual Use : Never take both medications simultaneously doing so increases side effect risks without improving results

Research shows that patients who align their eating patterns with tirzepatide's mechanism of action experience fewer side effects and faster progress toward their goals
Substances that neuralize free radicals are referred to as antioxidants